Products: Primary Antibodies

Anti-LRRK2/Dardarin (N-terminus) Antibody (8G10)

from NeuroMab

Product Summary:

Detect LRRK2/Dardarin (N-terminus) with this antibody validated for WB, IHC, ICC.

PRODUCT OPTIONS

Brand	Catalog #	Option	Volume	Concentration	Price
Brand	Catalog # 75-308	Option Purified	Volume 100 µL	Concentration 1 mg/mL	Price $325.00
Brand	Catalog # 73-308	Option TC Supernatant	Volume 5 mL	Concentration Lot dependent	Price $325.00

"TC Supernatant" vs. "Purified"

TC Supernatant
Hybridoma tissue-culture supernatant (5mL) generally containing 10-50 ug/mL monoclonal antibody (clone-dependent) can be a very economical choice. Supernatant is suitable for most applications including Western Blot, immunocytochemistry, immunohistochemistry etc. For applications requiring higher antibody concentration or purity (such as immunoprecipitation, microinjection, or conjugation) it is recommended that you purchase the purified form of the antibody (supplied at 1mg/mL).

Purified mAbs
Produced by in vitro bioreactor culture of hybridoma lines followed by Protein A affinity chromatography. Purified mAbs are >90% specific antibody at 1mg/mL.

Validation Images

Product Details

Antibody Type:

Monoclonal

Host Species:

Mouse

Antibody Isotype:

IgG1

Species Reactivity:

Human Mouse Rat

Applications:

ICC IHC WB

Target Description:

LRRK2 (also known as PARK8) encodes a protein with 5 putative functional domains: an N-terminal leucine-rich repeat (LRR) domain, a Roc (Ras of complex protein) domain that shares sequence homology to the Ras-related GTPase superfamily, a COR (C-terminal of Roc) domain, a mitogen-activated protein kinase kinase kinase (MAPKKK) domain, and a C-terminal WD40 repeat domain. Mutation in this gene is one of the most common causes of inherited Parkinson disease (Gandhi et al., 2008). LRRK2 was originally identified as a putative disease-causing transcript (DKFZp434H2111) within a 2.6-Mb region encompassing a locus for Parkinson disease-8 (PARK8). Northern blot analysis detected a 9-kb mRNA transcript in all tissues tested, including brain. The authors named the protein product dardarin, derived from the Basque word dardara, meaning tremor. LRRK2/dardarin is also known to positively regulate autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway and together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner. LRRK2/PARK8 is also known to regulate neuronal process morphology in the intact central nervous system (CNS) and play a role in synaptic vesicle trafficking.

Immunogen:

Fusion protein amino acids 100-500 (N-terminus) of human LRRK2 (also known as Leucine-rich repeat serine/threonine-protein kinase 2, Dardarin and PARK8, accession number Q5S007) Mouse: 82% identity (332/401 amino acids identical)
Rat: 82% identity (330/401 amino acids identical)
30% identity with LRRK1 This NeuroMab antibody is considered "Restricted" and is therefore not available for commercial re-distribution on a for-profit basis.

Protein Name(s):

Leucine-rich repeat serine/threonine-protein kinase 2 (EC 2.7.11.1) (Dardarin)

Gene Name(s):

LRRK2 PARK8

Antibody Registry ID:

Purified: AB_2315882
TC Supernatant: AB_2315881

Antibody Validation and Application Notes

This antibody has been validated using the following assays:

Knockout Validation:

This antibody has been knockout-validated in mouse brain (by Western blot and/or immunohistochemistry).

Western Blot:

This antibody recognizes a single immunoreactive band of expected molecular weight when used to probe brain lysate.

Immunocytochemistry:

This antibody shows the expected staining pattern when used to stain COS cells overexpressing target.

Immunohistochemistry:

This antibody shows the expected immunoperoxidase-diaminobenzidine / immunofluorescence staining pattern when used to stain brain sections.

Molecular Weight:

>200 kDa

Quality Control

The following quality control assay is performed on each new lot of this antibody to ensure it meets designated performance requirements.

Each new lot of this antibody is tested to confirm that it recognizes a single immunoreactive band of expected molecular weight when used to probe brain lysate.